Collagen Solutions PLC Director/PDMR Shareholding (8996B)
26 September 2018 - 12:05AM
UK Regulatory
TIDMCOS
RNS Number : 8996B
Collagen Solutions PLC
25 September 2018
Collagen Solutions Plc
(the "Company" or the "Group")
Director/PDMR Dealing
The Company today announces that on 25 September 2018 David
Evans, Chairman of the Company, has purchased 650,000 ordinary
shares in the Company ("Ordinary Shares") at 3.75 pence per
Ordinary Share.
Following these purchases, David Evans' total beneficial holding
in the Company has increased to 43,187,411 Ordinary Shares
representing 13.31 per cent. of the issued ordinary share capital
of the Company.
The Company makes the following disclosures in accordance with
article 19(3) of the Market Abuse Regulation:
1 Details of the person discharging managerial responsibilities / person closely associated
a) Name David Evans
2 Reason for the notification
a) Position/status Chairman
b) Initial notification / Amendment Initial
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name COLLAGEN SOLUTIONS PLC
b) LEI 213800IFY1CVGRGETL95
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the financial instrument, type of instrument Ordinary shares of 1p each
Identification code ISIN: GB00B94T6Y14
b) Nature of the transaction Purchase of Ordinary Shares
c) Price(s) and volume(s) Price(s) Volume(s)
3.75p per share 650,000
d) Aggregated information
- Aggregated volume N/A - single transaction
- Price
e) Date of the transaction 25 September 2018
f) Place of the transaction London Stock Exchange, XLON
Enquiries:
Collagen Solutions Plc
Jamal Rushdy, CEO Via Walbrook
Hilary Spence, CFO
Cenkos Securities Plc (Nominated
Adviser and Broker)
Steve Cox (Corporate Finance) Tel: 0207 397 8900
Stephen Keys
Walbrook PR Ltd Tel: 020 7933 8780 or collagen@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
Helen Cresswell Mob: 07841 917 679
About Collagen Solutions:
Collagen Solutions Plc is a global supplier, developer, and
manufacturer of medical grade collagen, tissues, and related
medical devices and components for use in regenerative medicine,
medical devices and in-vitro diagnostics and research. The Company
is also expanding its range of biomaterials-based finished medical
devices based on its internal and acquired intellectual property
for commercialisation with partners via licensing and distribution
arrangements, including ChondroMimetic(R). The Company's products
are used in a wide variety of applications including orthopaedics,
cardiovascular, dental, plastic surgery, wound healing, neurology
and urology.
For more information go to: www.collagensolutions.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHFKPDKQBKDNCB
(END) Dow Jones Newswires
September 25, 2018 10:05 ET (14:05 GMT)
Collagen Solutions (LSE:COS)
Historical Stock Chart
From Apr 2024 to May 2024
Collagen Solutions (LSE:COS)
Historical Stock Chart
From May 2023 to May 2024